Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | ACHE | P22303 | 4/20 | 0.43 |
| ▸ | BACE1 | P56817 | 3/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894392 | 0.86 | SIGMAR1 (0.59) | SIGMAR1ACHEMC4RKMT2ADRD4 | |
| SCHEMBL10259180 | 0.82 | SIGMAR1 (0.50) | SIGMAR1ACHEBACE1MC4RKMT2A | |
| SCHEMBL894517 | 0.82 | SIGMAR1 (0.50) | SIGMAR1ACHEBACE1KMT2ABCHE | |
| SCHEMBL25431096 | 0.82 | ALDH1A1 (0.52) | SIGMAR1KMT2ALMNAALDH1A1CYP3A4 | |
| SCHEMBL10259175 | 0.78 | ALDH1A1 (0.56) | SIGMAR1ACHEBACE1LMNABCHE | |
| SCHEMBL13668181 | 0.75 | DRD4 (0.70) | SIGMAR1GAADRD4 | |
| SCHEMBL25430929 | 0.73 | LIPG (0.43) | SIGMAR1ACHEMC4RGAALMNA | |
| SCHEMBL895077 | 0.72 | SIGMAR1 (0.61) | SIGMAR1ACHEMC4RDRD4LMNA | |
| SCHEMBL18574648 | 0.72 | SIGMAR1 (0.61) | SIGMAR1MC4RKMT2ADRD4LMNA | |
| SCHEMBL1491819 | 0.70 | SIGMAR1 (0.47) | SIGMAR1ACHEKMT2ADRD4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | SIGMAR1 4165/4885ACHE 4870/4885BACE1 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.